{"id":35510,"date":"2020-12-21T16:13:12","date_gmt":"2020-12-21T16:13:12","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=35510"},"modified":"2021-03-18T09:27:53","modified_gmt":"2021-03-18T09:27:53","slug":"benjamin-doranz","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/","title":{"rendered":"Benjamin Doranz"},"content":{"rendered":"<div class=\"vgblk-rw-wrapper limit-wrapper\">\n<h2>Benjamin Doranz, PhD, MBA<\/h2>\n<h4>President &amp; CEO at Integral Molecular<\/h4>\n\t<p>Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company&#8217;s growth since its inception, bringing five different technologies from research to market.<\/p>\n<p>He is an inventor on six of the company&#8217;s patents, the principal investigator on over 30 NIH grants, and an author on over 90 publications, including articles published in Cell, Science, and Nature. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania and an MBA from Wharton.<\/p>\n\t\t\t\t\t\t\t<img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery.jpg\" alt=\"Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery\" itemprop=\"image\" height=\"1224\" width=\"820\" title=\"Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery\" onerror=\"this.style.display='none'\" sizes=\"(max-width: 768px) 100vw, 100vw\" srcset=\"data:image\/svg+xml;utf8,<svg%20xmlns=&quot;http:\/\/www.w3.org\/2000\/svg&quot;%20viewBox=&quot;0%200%20820%201224&quot;%20height=&quot;1224px&quot;%20width=&quot;820px&quot;\/>&#8221; data-srcset=&#8221;https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-201&#215;300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-686&#215;1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-768&#215;1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-630&#215;940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-420&#215;627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_gallery-315&#215;470.jpg 315w&#8221;>\t\t\t\t\t\t\t\n<h3>\n\tLessons in Discovering Antibodies against GPCRs, Ion Channels, and Transporters\n\t<\/h3>\n<h4>\n\t\t\t<a href=\"#\" title=\"On the Web\" target=\"_self\" rel=\"noopener\">\n\tOn the Web\n\t\t\t<\/a>\n\t<\/h4>\n\t\n<h4>\n\t\t\t<a href=\"#\" title=\"On LinkedIn\" target=\"_self\" rel=\"noopener\">\n\tOn LinkedIn\n\t\t\t<\/a>\n\t<\/h4>\n<\/div><!-- .vgblk-rw-wrapper -->","protected":false},"excerpt":{"rendered":"<p>Benjamin Doranz, PhD, MBA President &amp; CEO at Integral Molecular Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company&#8217;s growth since its inception, bringing five different technologies from research to market. He is an inventor on six of the company&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":35515,"parent":34722,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-35510","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Benjamin Doranz &#8226; BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Benjamin Doranz &#8226; BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-18T09:27:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/\",\"name\":\"Benjamin Doranz &#8226; BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg\",\"datePublished\":\"2020-12-21T16:13:12+00:00\",\"dateModified\":\"2021-03-18T09:27:53+00:00\",\"description\":\"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg\",\"width\":900,\"height\":900},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibody Engineering &#038; Therapeutics 2021 Speakers\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Benjamin Doranz\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow&#039;s healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Benjamin Doranz &#8226; BioTech Pharma Summit","description":"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/","og_locale":"en_US","og_type":"article","og_title":"Benjamin Doranz &#8226; BioTech Pharma Summit","og_description":"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-18T09:27:53+00:00","og_image":[{"width":900,"height":900,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/","name":"Benjamin Doranz &#8226; BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg","datePublished":"2020-12-21T16:13:12+00:00","dateModified":"2021-03-18T09:27:53+00:00","description":"Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company\u2019s growth since its inception","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/12\/Benjamin_Doranz_integral_molecular_BioTech_Pharma_Summit_profile.jpg","width":900,"height":900},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/benjamin-doranz\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Antibody Engineering &#038; Therapeutics 2021 Speakers","item":"https:\/\/www.biotechpharmasummit.com\/index.php\/antibody-engineering-therapeutics-2021-speakers\/"},{"@type":"ListItem","position":3,"name":"Benjamin Doranz"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow&#039;s healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=35510"}],"version-history":[{"count":5,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35510\/revisions"}],"predecessor-version":[{"id":35896,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/35510\/revisions\/35896"}],"up":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/34722"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/35515"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=35510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}